Effect of MeCP2 on TGF- β 1-induced Extracellular Matrix Production in Nasal Polyp-derived Fibroblasts

Abstract

Purpose

Methyl-CpG-binding protein 2 (MeCP2), known as a transcriptional regulator, has been suggested to play an important role in myofibroblast differentiation in the lung. The purpose of this study was to investigate the role of MeCP2 in transforming growth factor (TGF)-β1-induced myofibroblast differentiation and extracellular matrix (ECM) production in nasal polyp-derived fibroblasts (NPDFs).

Methods

To identify the expression of MeCP2 in nasal polyp tissues, immunohistochemistry staining and Western blot were performed. TGF-β1-induced NPDFs were treated with 5-azacytidine, a DNA methylation inhibitor, and the expression levels of α-SMA and fibronectin were determined by semiquantitative reverse transcription polymerase chain reaction, immunoﬂuorescent staining, and Western blotting. The total soluble collagen was analyzed by the Sircol collagen assay. MeCP2 silenced by MeCP2-specific small interference (si) RNA was verified by Western blot.

Results

The expression levels of MeCP2 increased in nasal polyp tissues compared to normal inferior turbinate tissues. 5-Azacytidine significantly inhibited the expression of α-SMA and fibronectin mRNA in a dose-dependent manner. In addition, 5-azacytidine suppressed collagen production and the expression of MeCP2 in the same manner. The expression levels of a-SMA and collagen production were significantly blocked by MeCP2 silencing in TGF-β1-induced NPDFs.

Conclusions

Our data suggest that MeCP2 plays an essential role in TGF-β1-induced myofibroblast differentiation and ECM production in NPDFs.

Keywords

nasal polyp myofibroblast extracellular matrix TGF-β1 MeCP2

Get full access to this article

View all access options for this article.

References

Thomas

Yawn

Price

Lund

Mullol

Fokkens

; European Position Paper on Rhinosinusitis and Nasal Polyps Group. EPOS primary care guidelines: European position paper on the primary care diagnosis and management of rhinosinusitis and nasal polyps 2007—a summary. Prim Care Respir J. 2008; 17:79–89.

Bachert

Zhang

Gevaert

Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis.

J Allergy Clin Immunol. 2015; 136:1431–1440.

Ball

Mann

Wilson

Fisher

AJ.

The role of the fibroblast in inflammatory upper airway conditions.

Am J Pathol. 2016; 186:225–233.

Serpero

Petecchia

Sabatini

et al . The effect of transforming growth factor (TGF)-beta1 and (TGF)-beta2 on nasal polyp fibroblast activities involved upper airway remodeling: modulation by fluticasone propionate. Immunol Lett. 2006; 105:61–67.

Nakagawa

Yamane

Nakai

Shigeta

Takashima

Takeda

Comparative assessment of cell proliferation and accumulation of extracellular matrix in nasal polyps.

Acta Otolaryngol Suppl. 1998; 538:205–208.

Wang

Escudier

Roudot-Thoraval

Abd-Al Samad

Peynegre

Coste

Myofibroblast accumulation induced by transforming growth factor-beta is involved in the pathogenesis of nasal polyps.

Laryngoscope. 1997; 107:926–931.

Jaenisch

Bird

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals.

Nat Genet. 2003; 33 Suppl:245–254.

Wade

PA.

Methyl CpG-binding proteins and transcriptional repression.

Bioessays. 2001; 23:1131–1137.

Chahrour

Jung

Shaw

et al . MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008; 320:1224–1229.

10.

Mann

Chu

Maxwell

et al . MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology. 2010; 138:705–714, 714.e1–714.e4.

11.

Gharaee-Kermani

Phan

SH.

Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis.

Am J Pathol. 2011; 178:1500–1508.

12.

Zhou

Sun

XH.

Zebularine suppresses TGF-beta-induced lens epithelial cell-myofibroblast transdifferentiation by inhibiting MeCP2. Mol Vis. 2011; 17:2717–2723.

13.

Christman

JK.

5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.

Oncogene. 2002; 21:5483–5495.

14.

Holliday

Pugh

JE.

DNA modification mechanisms and gene activity during development.

Science. 1975; 187:226–232.

15.

Lee

Voo

Skalnik

DG.

Identification and characterization of the DNA binding domain of CpG-binding protein.

J Biol Chem. 2001; 276:44669–44676.

16.

Amir

Van den Veyver

Wan

Tran

Francke

Zoghbi

HY.

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.

Nat Genet. 1999; 23:185–188.

17.

Yang

Tao

Huang

et al . DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis. Cell Signal. 2013; 25:1202–1211.

18.

Cho

Moon

Park

et al . Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts. Clin Exp Allergy. 2012; 42:872–882.

19.

Mann

Oakley

Akiboye

Elsharkawy

Thorne

Mann

DA.

Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis.

Cell Death Differ. 2007; 14:275–285.

20.

Braiteh

Soriano

Garcia-Manero

et al . Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res. 2008; 14:6296–6301.

21.

Quintás-Cardama

Tong

Kantarjian

et al . A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008; 22:965–970.

22.

Esteller

Herman

JG.

Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours.

J Pathol. 2002; 196:1–7.

23.

Santini

Kantarjian

Issa

JP.

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

Ann Intern Med. 2001; 134:573–586.